Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

Peer Review reports

Original Submission
11 Aug 2021	Submitted	Original manuscript
29 Sep 2021	Author responded	Author comments - Sandra Neumann
Resubmission - Version 2
29 Sep 2021	Submitted	Manuscript version 2
Publishing
4 Oct 2021	Editorially accepted
29 Oct 2021	Article published	10.1186/s12883-021-02430-2

Back to article page